2012 ACR/ARHP Program Book

420 Pages·2012·13.84 MB·English

B:8.625 in
T:8.375 in
S:6.875 in
When you have decided a biologic is the next step
Choose
ENBREL
for appropriate moderate
to severe RA patients
ENBREL provided rapid and sustained efficacy
Visit us at iAnC Rp a20ti Reenstpso nwseitsh a tm Woeedke 2r,a Yteea rt 1o, asnedv Yeeraer 3R (ANRI) were1: S:9.875 in T:10.875 in B:11.125 in
booth 707 44%, 75%, and 52% for ENBREL + MTX*
19%, 59%, and 33% for MTX only
*P<0.001 vs MTX at all timepoints
NRI=Nonresponder imputation
Indication
A AD875" 5" ENBREL is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the
0 ACR J5" x 10.5" " x 9.87 pacrotigvree RssAio. nE NoBf RstErLu cctaunr able d ianmitiaagtee,d a inn dc oimmpbrionvaitniogn p whiytshi cmael tfhuontcrteioxnat ien (pMaTtXie)n otsr uwsiethd maloondee.r ately to severely
2725
ENEBRO1 8.3TRIM: .1BLEED:LIVE: 6.87 IEinmNcpBluoRdrtEinaLgn tht aSusab feberetcyeu nlIo nssfhiosor mw(TnaB tti)oo, n binaccrteearsiael tsheep sriiss,k ionfv asseirvieo ufsu ningfaelc tiniofencst iloenasd in(sgu tcoh haoss phiitsatloizpalatisomn oosri sd),e aatnhd,
infections due to other opportunistic pathogens, and should be discontinued if a patient develops a serious
infection or sepsis. Test for latent TB (if positive, start treatment for TB prior to starting ENBREL) and
monitor for active TB during treatment. Lymphoma and other malignancies, some fatal, have been reported
program
in children and adolescents treated with tumor necrosis factor (TNF) blockers, including ENBREL.
Please see additional Important Safety Information and Brief Summary of Prescribing Information on the
adjacent pages.
7
7/1 TEMPO was a 3-year, multicenter, double-blind, clinical trial of 682 patients with moderately to severely active RA (mean disease duration: 7 years), who had an
F inadequate response to at least 1 DMARD excluding MTX. At baseline: patients were ≥18 years of age, MTX-naïve, had an ESR ≥28 mm/hr or CRP ≥20 mg/L, and were
J in ACR functional class I, II, or III.1,2 B O O K
Call ENBREL Support™ after you prescribe: Pre-meeting Courses: November 9-10, 2012
1-888-4ENBREL oPening leCture and awards, oPening event: November 10, 2012
www.enbrel.com/rheumpro sCientifiC sessions: November 10-14, 2012
B:8.625 in
T:8.375 in
S:6.875 in
Prescription Enbrel® (etanercept) is administered by injection. demyelinating disorders. Cases of transverse myelitis, optic
neuritis, multiple sclerosis, Guillain-Barré syndromes, other
IMPORTANT SAFETY INFORMATION peripheral demyelinating neuropathies, and new onset or
imPortant loCations exacerbation of seizure disorders have been reported in post-
SERIOUS INFECTIONS marketing experience with ENBREL therapy. Prescribers should
Patients treated with ENBREL are at increased risk for exercise caution in considering the use of ENBREL in patients
developing serious infections that may lead to hospitalization with preexisting or recent-onset central or peripheral nervous
aCr office . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .102A; Telephone: [phone] or death. Most patients who developed these infections were system demyelinating disorders.
taking concomitant immunosuppressants such as methotrexate
attendee lounge . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .ballroom Pre-Function or corticosteroids or were predisposed to infection because of CONGESTIVE HEART FAILURE
their underlying disease. ENBREL should not be initiated in the Cases of worsening congestive heart failure (CHF) and,
Business Center . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .L Street South Lobby (under escalator) presence of sepsis, active infections, or allergy to ENBREL or rarely, new-onset cases have been reported in patients taking
Career Connection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .exhibit Hall (Hall A), booth 945 its components. ENBREL should be discontinued if a patient ENBREL. Caution should be used when using ENBREL in
develops a serious infection or sepsis. Reported infections patients with CHF. These patients should be carefully monitored.
Child Care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Call for Location; Telephone: [phone] include: 1) Active tuberculosis (TB), including reactivation of HEMATOLOGIC EVENTS
latent TB. Patients with TB have frequently presented with Rare cases of pancytopenia, including aplastic anemia, some
Cme/internet Center . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Concourse (near entrance to Hall A) disseminated or extrapulmonary disease. Patients should fatal, have been reported. The causal relationship to ENBREL
Coat/Baggage Check . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .registration (Salons G-H-I) be tested for latent TB before ENBREL use and periodically therapy remains unclear. Exercise caution when considering
during therapy. Treatment for latent infection should be ENBREL in patients who have a previous history of significant
exhibit Hall . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall A initiated prior to ENBREL use, 2) Invasive fungal infections, hematologic abnormalities. Advise patients to seek immediate
including histoplasmosis, coccidioidomycosis, candidiasis, medical attention if they develop signs or symptoms of blood
first aid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .exhibit Hall (Hall A, bottom of escalator) aspergillosis, blastomycosis, and pneumocystosis. Patients dyscrasias or infection. Consider discontinuing ENBREL if
graffiti walls . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .exhibit Hall (Hall A) & Grand Lobby wprieths ehnits twopitlhas mdiosssiesm oinr aottehde, r riantvhaesri vteh afunn gloacl ailnizfeecdt, iodniss emasaey. significant hematologic abnormalities are confirmed.
Antigen and antibody testing for histoplasmosis may be HEPATITIS B VIRUS REACTIVATION
Hotel reservations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .registration (Salons G-H-I)
negative in some patients with active infection. Empiric Use of TNF blockers, including ENBREL, has been associated
industry-supported symposia information . . . . . . . . . . . . . . . .L Street South Lobby (under escalator) antifungal therapy should be considered in patients at risk for with reactivation of hepatitis B virus (HBV) in chronic carriers
invasive fungal infections who develop severe systemic illness, of this virus. The majority of these reports occurred in patients
innovation theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall A, booth 1451 and 3) Bacterial, viral, and other infections due to opportunistic on concomitant immunosuppressive agents, which may also
pathogens, including Legionella and Listeria. contribute to HBV reactivation. Exercise caution when
lost and found . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .ACr office (102A) considering ENBREL in patients identified as carriers of HBV.
The risks and benefits of treatment with ENBREL should be
membership Booth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .registration (Salons G-H-I) carefully considered prior to initiating therapy in patients ALLERGIC REACTIONS
1) with chronic or recurrent infection, 2) who have been exposed Allergic reactions have been reported in <2% of patients in
newsroom . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .203A-b; Telephone: [phone] to TB, 3) who have resided or traveled in areas of endemic clinical trials of ENBREL.
TB or endemic mycoses, or 4) with underlying conditions that
nursing mothers’ room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Salon D IMMUNIZATIONS
may predispose them to infections such as advanced or poorly
Live vaccines should not be administered to patients on ENBREL.
Poster Hall . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall b controlled diabetes. Patients should be closely monitored JIA patients, if possible, should be brought up to date with
for the development of signs and symptoms of infection
all immunizations prior to initiating ENBREL. In patients with
Prayer room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Salon e (east building, Street Level) during and after treatment with ENBREL, including the
exposure to varicella virus, consider temporary discontinuation
possible development of TB in patients who tested negative
recharge areas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . exhibit Hall (Hall A, main aisles), of ENBREL and prophylactic treatment with Varicella Zoster
registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .aASanttldoe nnladsr egGee- HLmo-Ieu (enLtiegnveeg ( lbr 1oa)ollrmoso m Pre-Function) fMLroeyArpm oLlarpIttGheeoNndmAt iaTNn BC a cInpEhdrSii lodorrt ethnoe rina inmtdiaa tlaiigndngoa ltenhsceciereasnp,t y s.po amtiee nftast atl,r ehaatveed bweiethn IAAlimkuUemtT osuOaynnIneMtd iGMbroolUomdbNieeuI slToi nYrm. aauyt odiemvmeluonpe whietpha EtiNtiBs RmEaLy, oacncdu rr.a Trehleys elu pmuasy- S:9.875 in T:10.875 in B:11.125 in
tumor necrosis factor (TNF) blockers, including ENBREL.
resolve upon withdrawal of ENBREL. Stop ENBREL if lupus-like
resource Center . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .L Street bridge (Level 2) In adult clinical trials of all TNF blockers, more cases of syndrome or autoimmune hepatitis develops.
lymphoma were seen compared to control patients. The risk of
restaurant reservations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Grand Lobby lymphoma may be up to several-fold higher in RA and psoriasis WEGENER’S GRANULOMATOSIS PATIENTS
Rheumatology Research Foundation patients. The role of TNF blocker therapy in the development of The use of ENBREL in patients with Wegener’s granulomatosis
malignancies is unknown. receiving immunosuppressive agents (e.g., cyclophosphamide)
5K run/walk registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .registration (Salons G-H-I) is not recommended.
Cases of acute and chronic leukemia have been reported in
Rheumatology Research Foundation Booth . . . . . . . . . . . . . . .L Street bridge (Level 2) association with postmarketing TNF blocker use in RA and MODERATE TO SEVERE ALCOHOLIC HEPATITIS
other indications. The risk of leukemia may be higher in patients Based on a study of patients treated for alcoholic hepatitis,
SRdrehiobsenbsuoioomrnnsa ’Sd tleoiolselutocrngtib gylue oRti u .eo .nsn .eg . .ea . .r . . .ch . . . . . .F . . .o . . .u . . .n . . .d . . .a . . .ti . . . . . .o . . .n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Weraeesgtsi sto torvavetierolrolnoo o(kSk (a 2(l2onnndds F GFlol-ooHor-)rI )) 120 ACR JA AD375" x 10.875"125" 75" x 9.875" wMrEaelNilept Bplhoaa RrnRttEoieAemLd n(. ataPs ipn aepa nrtridp ooi anxdntciimicore enansa-ttkmsesien leyd lt ea 2rrxnei-saofaokmtm lefdiadon) r ats thswkikaoiintinnnh s ct c hasaTenhnN cogcFeuee rlrn d.be( NlrboaMecl kSpceCoornp)s su,h ildaainevticreoel undbd. eifneongr etATtorxhDi aeesVlr escEmv iweRsoereSse rctE e aa cEluciontVoimjoEhenmocN tlwiToiconSh nhley ens p irutaeestp iintoriegrsta .EecNdti BoanRd,E viLen rfisenec p taieotvniee, nnattnss dwi niht ehRa mAda occdlheineri.ac tIanel
sshpueattklee rBs’u lso .u .n . .ge . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1L 4S1treet ENEBRO 8.TRIM: .BLEED:LIVE: 6.8 hPInae pldfa iatoitfe rnticths eP w arhetopie oinnritttseiadt emd athliegrnaapnyc aiets ≤ 1w8e yreea lrysm ofp ahgoem, aapsp (rHoxoidmgaktienl’ys csilminiiclaarl ttori athlso osef arell pootrhteerd a idnu RltA i ncdliinciactailo tnrsia, lasd. verse events were
and non-Hodgkin’s lymphoma). Other cases included rare DRUG INTERACTIONS
speaker ready room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .156 malignancies usually associated with immunosuppression and The use of ENBREL in patients receiving concurrent
malignancies that are not usually observed in children and cyclophosphamide therapy is not recommended. The risk of
visitor information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Grand Lobby adolescents. Most of the patients were receiving concomitant serious infection may increase with concomitant use of abatacept
immunosuppressants. therapy. Concurrent therapy with ENBREL and anakinra is not
wheelchairs (complimentary-limited availability) . . . . . . . . . .Information Desk (Grand Lobby)
recommended. Hypoglycemia has been reported following
NEUROLOGIC EVENTS
wi-fi way . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .exhibit Hall (Hall A) Treatment with TNF-blocking agents, including ENBREL, has been initiation of ENBREL therapy in patients receiving medication
for diabetes, necessitating a reduction in antidiabetic medication
associated with rare (<0.1%) cases of new onset or exacerbation
in some of these patients.
7 of central nervous system demyelinating disorders, some
1
special needs F 7/ presenting with mental status changes and some associated Please see adjacent Brief Summary of Prescribing Information.
If you require special arrangements, please contact the ACr office (102A); Telephone: [phone]. J with permanent disability, and with peripheral nervous system
emergency Contact information References: 1. Data on file, Pfizer Inc. 2. Klareskog L, van der Heijde D, de Jager JP, et al; for the TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study
investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled
Space is provided on the back of your badge to list name and telephone numbers of your emergency
trial. Lancet. 2004;363:675-681.
contacts. Please complete this information before inserting your badge in your badge holder.
© 2012 Amgen Inc., Thousand Oaks, CA 91320 and Pfizer Inc. All rights reserved. www.enbrel.com/rheumpro
61043-R4-V3 07-12
program
B O O K
ABOUT THE ANNUAL MEETING
Participation Statement
This annual meeting is sponsored by the American College of Rheumatology for educational purposes only. The material
presented is not intended to represent the only or the best methods appropriate for the medical conditions being discussed,
but rather is intended to present the opinions of the authors or presenters, which may be helpful to other healthcare
professionals at arriving at their own conclusions and consequent application. Attendees participating in this medical
education program do so with full knowledge that they waive any claim they may have against the College for reliance on
any information presented during these educational activities. The College does not guarantee, warrant or endorse any
commercial products or services.
The ACR’s CME purpose is to provide comprehensive education to improve the knowledge and performance of physicians,
scientists and other health professionals. The ACR will offer evidence-based educational activities designed to enhance
practice performance and improve the quality of care in those with or at risk for arthritis and rheumatic and musculoskeletal
diseases.
Global Learning Objectives
At the conclusion of the 2012 ACR/ARHP annual meeting, participants should be able to:
• identify recent developments in the diagnosis and management of patients with rheumatic diseases
• outline new technologies for the treatment of rheumatologic problems
• describe potential challenges in the delivery of care to patients with rheumatic diseases and to specify
possible solutions
• utilize new research data to improve the quality of care of patients with rheumatic diseases
• summarize recent rheumatology research findings
The program is the result of a planning process that identified educational needs to change or enhance the knowledge,
competence or performance of rheumatology professionals. The program’s content was derived from both needs assessment
and practice gap analysis that took professional activities, practice setting, ABIM recertification requirements and physician
attributes into account.
Printing of this publication is supported by Amgen, Inc. and Pfizer, Inc.
This publication was printed by an FSC validated printer on eco-friendly paper.
TABLE OF CONTENTS
POLICIES PRE-MEETING PROGRAM
Copyright Materials Policy .....................................11 Friday, November 9, 2012
Media ......................................................11
ACR Musculoskeletal Ultrasound Course for Rheumatologists –
Embargo Policy ...............................................11 Day One of Two ..............................................20
ACR Certified Rheumatology Coder Course: Unlock the Mystery:
MEETING INFORMATION
A Roadmap for Rheumatology Coding – Day One of Two ............21
Cell Phones, PDAs & Other Electronic Devices .....................12 ACR Basic Research Conference: Mesenchymal Cells in Rheumatic
Diseases: Tissue Erosion/Invasion vs. Fibrosis – Day One of Two ......22
Children ....................................................12
ACR Clinical Research Conference: Pain Research: New Methods
Child Care ...................................................12
and Challenges – Day One of Two ...............................22
Nursing Mothers’ Room .......................................12
ACR/ABIM Maintenance of Certification Learning Session –
Exhibit Hall ..................................................12
2012 Update in Rheumatology .................................21
Meeting Room Capacity/Important First Safety Information ..........12
Saturday, November 10, 2012
Photograpy and Videotaping ...................................12
ACR Musculoskeletal Ultrasound Course for Rheumatologists –
Name Badges ................................................12
Day Two of Two ..............................................23
No Smoking .................................................12
ACR Review Course ...........................................24
MEETING NAVIGATION GUIDE ACR Basic Research Conference: Mesenchymal Cells in Rheumatic
Diseases: Tissue Erosion/Invasion vs. Fibrosis – Day Two of Two ......25
Track Icons ..................................................13
ARHP Clinical Focus Course: Treating the Patient with
Session Formats ..............................................13 Osteoarthritis: Interventions, Innovations and Clinical Insights .......26
Abstract Formats .............................................13 CORC Pre-meeting Course for Practice Managers: Helping You
Manage A Profitable Practice ..................................27
MEETING SERVICES ACR Clinical Research Conference: Pain Research: New Methods
and Challenges – Day Two of Two ...............................27
My Annual Meeting ..........................................15
ACR Certified Rheumatology Coder Course Examination:
Resource Center ..............................................15
Unlock the Mystery: A Roadmap for Rheumatology Coding –
Membership Booth ...........................................15
Day Two of Two ..............................................29
Lost and Found ...............................................15
Newsroom ..................................................16 ACR/ARHP ANNUAL MEETING
Attendee Lounge .............................................16 SCIENTIFIC PROGRAM
Announcement Boards ........................................16
Saturday, November 10, 2012
Career Connection ............................................16
ACR/ARHP Opening Lecture and Awards ..........................29
Registration Shuttle Bus .......................................16
Speaker Ready Room ..........................................16 Sunday, November 11, 2012
Wi-Fi Way and Recharge Access .................................16
ACR Sessions
Rheumatology Research Foundation Booth .......................17
Modifying Causal Risk Factors that Influence the Incidence of Falls
Rheumatology Research Foundation Donors’ Lounge ...............17 by Older Adults ..............................................29
Rheumatology Research Foundation 5K Run/Walk ..................17 Year in Review ...............................................30
Genetics as a Tool for Elucidating Autoimmune Disease
SPECIAL OFFERS
Pathogenesis ................................................30
SessionSelect ................................................18 Tips for Publishing Your Work in a Peer-Reviewed Medical
Journal .....................................................30
What Would Make the Meeting Better ...........................19
Medical Bag .................................................19 ARHP Sessions
ARHP First-time Attendee Orientation ............................30
POSTER SESSIONS
ARHP Moderators Orientation ..................................30
Poster Session Presenter Instructions ............................19
Meet the Professor Sessions
ACR Poster Presenter No-show Policy ............................19
Behçet’s Disease (001) ........................................31
Guided Poster Tours ...........................................19
Controversies in Sjögren’s Syndrome (002) ........................31
Infections with Biologics (003) ..................................31
Pediatrics: Dermatomyositis (004) ...............................31
Pediatrics: Difficult to Treat Juvenile Idiopathic Arthritis (005) ........31
2 2012 Program Book
TABLE OF CONTENTS
Rheumatoid Arthritis: Biological Agents (006) . . . . . . . . . . . . . . . . . . . . .31 ARHP Networking Event
Spondylarthropathy: An Update (007) . . . . . . . . . . . . . . . . . . . . . . . . . . . .31 Networking Forum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .37
Systemic Arthritis and Still’s Disease (008) . . . . . . . . . . . . . . . . . . . . . . . .31
ACR Meet the Professor Sessions
Systemic Lupus Erythematosus: Central Nervous System (009) . . . . . . .31
Adult Inflammatory Myopathy (011) . . . . . . . . . . . . . . . . . . . . . . . . . . . . .38
Vasculitis Mimics (010) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .31
Cutaneous Vasculitis (012) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .38
ACR Workshops Inflammatory Eye Disease/Uveitis (013) . . . . . . . . . . . . . . . . . . . . . . . . . .38
Basic Statistical Concepts for the Medical Researcher (201) . . . . . . . . . .31 Myopathy: Issues in Diagnosis and Treatment (014) . . . . . . . . . . . . . . . .38
Clinical Anatomy and Physical Exam: Essential Tools in Lower Osteoporosis: Novel Treatments (015) . . . . . . . . . . . . . . . . . . . . . . . . . . .38
Extremity Regional Pain Syndromes (202) . . . . . . . . . . . . . . . . . . . . . . . .31 Pediatrics: Periodic Fevers in Children (016) . . . . . . . . . . . . . . . . . . . . . . .38
Dermatopathology of Rheumatic Diseases (203) . . . . . . . . . . . . . . . . . . .31 Polymyalgia Rheumatica (017) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .38
Musculoskeletal Exam Skills I: General Musculoskeletal Pregnancy in Rheumatic Diseases (018) . . . . . . . . . . . . . . . . . . . . . . . . . .38
Examination for Arthritis (204) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .31
Systemic Lupus Erythematosus: Novel Treatments (019) . . . . . . . . . . . . .38
ACR Sessions Vitamin D and Bone Health (020) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .38
Advances in the Biology of Aging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .31
ACR Sessions
CORC FORUM: Achieving Economic Goals in an Era of Healthcare
Endoplasmic Reticulum Stress Unfolded Protein Response in
Reform . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .31
Immunity and Inflammation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .38
New Therapies for Modulating Signaling in Rheumatoid Arthritis . . . . .32
Mechanisms of Pain in Rheumatic Diseases . . . . . . . . . . . . . . . . . . . . . . .38
The Plasticity of T Regulatory Cells and their Role in Autoimmunity . . . . 32
Preoperative Assessment and Perioperative Management
Update on Stroke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .32 of the Patient with Rheumatic Disease: What Every
Extra-articular Involvement in Rheumatoid Arthritis . . . . . . . . . . . . . . . .32 Rheumatologist Should Know (Clinical Review) . . . . . . . . . . . . . . . . . . . .38
Medical Education: The Year in Review . . . . . . . . . . . . . . . . . . . . . . . . . . .32
ACR Workshops
ACR Poster Session A and Poster Tours Designing a Website for Your Practice (208) . . . . . . . . . . . . . . . . . . . . . . .39
Abstracts (#1-724) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .32 Muscle Involvement in Rheumatic Diseases (209) . . . . . . . . . . . . . . . . . .39
Physical Examination Skills for Improved Detection of Synovitis
ARHP Session
and Cervical Thoracolumbar Disorders (210) . . . . . . . . . . . . . . . . . . . . . .39
ARHP Keynote Address: It’s Not Child’s Play: Growing Up With
Renal Histopathology in Systemic Lupus Erythematosus and
and Mastering Juvenile Idiopathic Arthritis from the Child’s
Vasculitis (211) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .39
Perspective . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .33
ACR Sessions
Rheumatology Research Foundation Special Session
Complementary and Alternative Medicine: Evidence-based
Oscar S. Gluck, MD, Memorial Lectureship: Bone Wasn’t
Options for Arthritis Patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .39
Built in a Day: New Insights into Destruction and Repair in
Rheumatic Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .33 Prospects for Prevention and Cure of Rheumatoid Arthritis . . . . . . . . . .39
The Great Debate: In 2012 what are the Roles of Cyclophosphamide
Exhibits and Innovation Theater
versus Rituximab in ANCA-Associated Vasculitis . . . . . . . . . . . . . . . . . . .39
See page 316 of a complete listing of Innovation Theater. . . . . . . . . . . . .33
Update on Treatment of Systemic Lupus Erythematosus . . . . . . . . . . . . .39
ACR Workshops
ACR Concurrent Abstract Sessions
Adult Musculoskeletal Upper Examinations (205) . . . . . . . . . . . . . . . . . .33
Biology and Pathology of Bone and Joint: Osteoarthritis
Musculoskeletal Ultrasound (206) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .33 (#730-735) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .40
Renal Histopathology in Systemic Lupus Erythematosus and Cytokines, Mediators, and Gene Regulation I (#736-740)
Vasculitis (207) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .33 Includes 2011 Lee C. Howley, Sr. Prize for Arthritis Research
Introductory Talk I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .40
ACR Plenary Session I: Discovery 2012
Epidemiology and Health Services Research I: Epidemiology
Abstracts (#725-729) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .33
and Outcomes in Rheumatic Disease (#741-746) . . . . . . . . . . . . . . . . . .41
ARHP Sessions Miscellaneous Rheumatic and Inflammatory Diseases:
Hands: Non-Surgical Management and Bracing – What You Periodic Fever Syndromes (#747-752) . . . . . . . . . . . . . . . . . . . . . . . . . . .41
Don’t Know Can Hurt You . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37 Muscle Biology, Myositis and Myopathies: Classification,
New Medication Developments in Rheumatology . . . . . . . . . . . . . . . . . .37 Treatment and Outcome in Idiopathic Inflammatory
Myopathies (# 753-758) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .42
Rheumatic Disease Update: Vasculitis . . . . . . . . . . . . . . . . . . . . . . . . . . . .37
Pediatric Rheumatology: Clinical and Therapeutic Disease I:
The 5A Approach to Physical Activity Counseling for
Juvenile Idiopathic Arthritis I (#759-764) . . . . . . . . . . . . . . . . . . . . . . . . .42
Arthritis Patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .37
Rheumatoid Arthritis – Clinical Aspects I: Risk Factors and
ACR Session Prediction of Rheumatoid Arthritis (#765-770) . . . . . . . . . . . . . . . . . . . .43
ACR Knowledge Bowl – Preliminary Round . . . . . . . . . . . . . . . . . . . . . . . .37
2012 Program Book 3
TABLE OF CONTENTS
Rheumatoid Arthritis Treatment – Small Molecules, Biologics Psoriatic Arthritis (026) ........................................56
and Gene Therapy: Comparative Efficacy and Novel Treatment Pulmonary Hypertension in the Rheumatic Diseases (027) ...........56
Strategies in Rheumatoid Arthritis (#771-776). . . . . . . . . . . . . . . . . . . . . 44
Rheumatoid Arthritis: Challenging Cases (028) .....................56
Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects
Rheumatoid Arthritis: Outcome Measures in Clinical
and Treatment: Spondyloarthritis I (#777-782) ....................45
Practice (029) ...............................................56
Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s –
Temporal Arteritis (030) .......................................56
Pathogenesis, Animal Models and Genetics (#783-788) .............45
ARHP Sessions
ARHP Sessions
Income Inequities Are Perilous to People with Arthritis ..............56
Non-pharmacological Management of Fibomyalgia: Your Toolbox .....46
Practice Management: Patients As Partners in Design and
Practice Managers: Improving Access and Website Marketing
Delivery (Practice Management Series) ..........................56
(Practice Management Series) ..................................46
Rheumatic Disease Update: Inflammatory Eye Disease ..............46 ARHP Concurrent Abstract Sessions
Pediatrics: Disease Flares (#861-865). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
ARHP Concurrent Abstract Sessions
Psychological Aspects of Rheumatologic Disease (#866-871) .........57
Foot and Gait Disorders (#789-794) ..............................47
Osteoarthritis (#795-800) ......................................47 Monday, November 12, 2012
ACR Workshops ACR Sessions
Dermatopathology of Rheumatic Diseases (212) ...................48 Clinicopathologic Conference: A Patient with Hepatitis C
and Inflammatory Polyarticular Arthritis .........................58
Musculoskeletal Exam Skills II: Regional Musculoskeletal
Examination of the Neck and Low Back (213) .....................48 Cross-Sectional Imaging Techniques for Rheumatology ..............58
Osteoporosis: Interpreting Dual Energy X-ray Absorptiometry Immune Tolerance: From Theory and Clinical Practice ...............58
and Clinical Risk Factors: The New Fracture Risk Assessment Synovial Immunobiology and Response to Therapy in
Algorithm (214) ..............................................48 Rheumatoid .................................................58
Synovial Fluid Analysis and Crystal Identification (215) ..............48
ARHP Sessions
ACR Sessions Disparities in the Use of Joint Arthroplasty: A Pervasive
Classification and Treatment of Sjögren’s Syndrome ................48 Matter Leading to Inequitable Care (Arthroplasty/Joint
Replacement Series) ..........................................58
Metabolic Abnormalities in Autoimmunity ........................48
Incorporating Physician Assistants and Nurse Practitioners
Puberty, Adolescence and Rheumatologic Disease .................48
into Rheumatology Practice ....................................59
Thieves’ Market: Show Me Your Best Cases .......................49
Infusion Room Information for Medical Professionals
Update on Psoriatic Arthritis and the Spondylarthropathies .........49X
(Infusion Series) .............................................59
ACR Concurrent Abstract Sessions New and Better Habits! Facilitating Patient Self-management
Fibromyalgia and Soft Tissue Disorders I (#801-806) ................49 with Proven Behavior Change Strategies .........................59
Imaging of Rheumatic Diseases I: Ultrasound and X-ray (#807-812) ....50 ACR Session
Metabolic and Crystal Arthropathies: Clinical (#813-818) ............50 ILAR – The Current Rheumatology Workforce Across the Globe .......59
Osteoporosis and Metabolic Bone Disease (#819-824) ..............51
ACR Meet the Professor Sessions
Rheumatoid Arthritis – Clinical Aspects II: Long-term Outcome
Crystal: Diagnosis and Management of Gout (031) .................60
of Rheumatoid Arthritis, Observational Studies (#825-830) ..........51
Osteoarthritis: Update 2012 (032) ...............................60
Rheumatoid Arthritis Treatment – Small Molecules, Biologics and
Gene Therapy: Efficacy and Safety of Novel Entities (#831-836) ......52 Pediatric Rheumatology for Adult Rheumatologists (033) ............60
Systemic Lupus Erythematosus – Clinical Aspects and Treatment I: Pediatrics: Spondylarthritis in Children (034) ......................60
Renal (#837-842) ............................................53 Psoriatic Arthritis (035) ........................................60
Systemic Lupus Erythematosus – Human Etiology and Rheumatoid Arthritis: Difficult Cases (036) ........................60
Pathogenesis I (#843-848) .....................................53
Rheumatoid Arthritis: Difficult Cases (037) ........................60
Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s –
Scleroderma: Systemic Sclerosis (038) ............................60
Clinical Aspects and Therapeutics I (#849-854) ....................54
Scleroderma: Systemic Sclerosis (039) ............................60
Vasculitis: Pathogenesis (#855-860) ..............................55
Vasculitis: Update (040) ........................................60
ACR Meet the Professor Sessions
ACR/ARHP Workshops
Ankylosing Spondylitis: 2012 Update (021) ........................56
Joint Injections (Knee and Ankle Prosthetics) (216) .................60
Antiphospholipid Syndrome (022) ...............................56
Musculoskeletal Ultrasound (217) ...............................60
Crystal: Diagnosis and Management of Gout (023) .................56
Peripheral Magnetic Resonance Imaging in Rheumatology
Immunodeficiency Syndromes (024) .............................56
Practice (218) ...............................................60
Pain: Evaluation and Treatment of Back Pain (025) .................56
X-ray Challenges in Rheumatic Diseases (219) .....................60
4 2012 Program Book
TABLE OF CONTENTS
ACR Sessions Dermatological Manifestations of Rheumatic Diseases (044) .........70
Epigenetic Factors in Autoimmune Disease ........................60 Hereditary Angioedema (045) ..................................70
New Anticoagulants: What a Hematologist Thinks a Pulmonary Manifestations of Rheumatic Disease (046) ..............70
Rheumatologist Needs to Know! ................................61 Raynaud’s and Digital Ischemia (047) .............................70
Rheumatology Research Foundation Special Session Scleroderma Mimics (048) .....................................70
Memorial Lectureship: Pathogenesis of Rheumatoid Vaccinations for Patients on Biologic Therapies (049) ...............70
Arthritis: The Voyage from Pre-Rheumatoid Arthritis to Joint Vasculitis: Update (050) ........................................70
Destruction .................................................61
ACR Sessions
ARHP Sessions
Complex Regional Pain Syndrome/Reflex Sympathetic
Clinical Trials: Participation and Recruitment ......................61 Dystrophy: Recent Advances, Current Thoughts ...................70
Infusion Reactions: Management and Prevention Innovation in Musculoskeletal Curriculum Development:
(Infusion Series) .............................................61 Lessons from New Medical Schools .............................70
Issues in the Management of Rheumatic Disease in Pediatric Rheumatology Town Hall Meeting .......................71
Patients Undergoing Joint Replacement (Arthroplasty/Joint
Scleroderma Bowel Disease: From Top to Bottom (Clinical Review) ....71
Replacement Series) ..........................................61
Rheumatic Disease Update: Gout ................................61 ACR/ARHP Workshops
Histopathology of Vasculitis (222) ...............................71
ACR Sessions
Joint Injections (Shoulder and Wrist Prosthetics) (223) ..............71
Creating an Efficient Rheum Practice .............................61
MRI in the Diagnosis and Management of Spondylarthritis:
Legislative Update from Capitol Hill ..............................62
A Clinician’s Guide (224) .......................................71
Update on Safety Issues in the Treatment of Rheumatic
Diseases – From the Food and Drug Administration and Beyond .....62 ACR Sessions
Curbside Consults – Ask the Professors ...........................71
Rheumatology Research Foundation Special Session
Macrophage and Dendritic cell Heterogeneity in Tissue
ACR REF Special Session: Clinician Scholar Educator Presentations ....62
Inflammation and Fibrosis .....................................71
ACR/ARHP Poster Session B, Thieves’ Market Posters and Mechanotransduction in Bone and Cartilage ......................72
Poster Tours Neuropsychiatric Lupus in Children and Adolescents ................72
Abstracts (#872-1592) .........................................62 Osteoporosis: From Bisphosphonates and Beyond. . . . . . . . . . . . . . . . . . 72
Exhibits and Innovation Theater ACR Concurrent Abstract Sessions
See page 316 of a complete listing of Innovation Theater. ............63 Cell-cell Adhesion, Cell Trafficking and Angiogenesis (#1599-1603)
Includes 2011 Lee C. Howley, Sr. Prize for Arthritis Research
ARHP Session Introductory Talk II ...........................................72
Distinguished Lecturer: Unraveling the “Go-Gene” .................63 Epidemiology and Health Services Research II: Epidemiologic
Risk Factors in the Development of Rheumatic Disease
ACR Workshops
(#1604-1609) ................................................73
Musculoskeletal Exam Skills III: Regional Musculoskeletal
Genetics and Genomics of Rheumatic Diseases (#1610-1615) ........73
Examination of the Shoulder and Knee (220) ......................63
Imaging of Rheumatic Diseases II: Magnetic Resonance
Osteoporosis: Interpreting Dual Energy X-ray Absorptiometry
Imaging (#1616-1621) ........................................74
and Clinical Risk Factors: The New Fracture Risk Assessment
Algorithm (221) ..............................................63 Infection-related Rheumatic Disease (#1622-1627) .................75
Metabolic and Crystal Arthropathies: Basic Science (#1628-1633) .....76
ACR Plenary Session II: Discovery 2012
Rheumatoid Arthritis – Animal Models (#1634-1639) ...............76
(Abstracts #1593-1598) ........................................64
Rheumatoid Arthritis Treatment – Small Molecules, Biologics
ACR Sessions and Gene Therapy: Safety I (#1640-1645) ........................77
ACR Knowledge Bowl – Final Round ..............................68 Systemic Lupus Erythematosus – Clinical Aspects and
Career Opportunities in Rheumatology: Making a Choice ............69 Treatment II: Clinical Aspects/Pregnancy (#1646-1651) .............78
New Developments in Systemic Juvenile Idiopathic Vasculitis: Clinical Trials (#1652-1657) ............................78
Arthritis Management ........................................69
ARHP Sessions
The Connected Rheumatology Practice: Electronic Health
Demystifying the Study Section: How Grants Are
Record and Social Media Implementation and Customization ........69
Reviewed and Scored .........................................79
ARHP Networking Event Depression in Rheumatic Diseases ...............................80
Networking at Noon ..........................................69 Minimizing Falls in Geriatric Rheumatic Populations ................80
Total Knee Arthroplasty Rehabilitation: Optimizing Functional
ACR Meet the Professor Sessions
Outcomes Through Examination of Patient Factors, Practice
Ankylosing Spondylitis: 2012 Update (041) ........................70
Variation and Best Practice Recommendations (Arthroplasty/
Basic Immunology for Clinical Rheumatologists (042) ...............70 Joint Replacement Series) .....................................80
Challenging Cases in Osteoporosis Management (043) ..............70
2012 Program Book 5
TABLE OF CONTENTS
ACR Workshops ARHP Concurrent Abstract Session
Getting Electronic Health Records Right (225) .....................80 Care of Patients With Rheumatoid Arthritis (#1718-1723) ...........89
Musculoskeletal Ultrasonography: Basic (226) .....................80
ACR Study Groups .............................................90
Patient Questionnaires: Multi-Dimensional Health Assessment
Questionnaire/Routine Assessment of Patient Index Data 3 Tuesday, November 13, 2012
and Beyond Toward a Standard, Scientific, Quantitative
ACR Sessions
Patient History (227) ..........................................81
Chronic Recurrent Multifocal Osteomyelitis .......................90
Systemic Sclerosis: How to Perform Skin Scores (228) ...............81
Molecular and Cellular Basis of Tissue Homing .....................91
ACR Sessions Update on Immune Mediated Glomerular Disease .................91
Aging and the Rheumatic Diseases ..............................81
Rheumatology Research Foundation Special Session
Dermatology Topics for Rheumatologists: What You Need to Know ....81
Paul Klemperer, MD Memorial Lectureship: Serum
Energetics, Metabolism and Osteoarthritis ........................81
Autoantibodies in Systemic Sclerosis: Usefulness in Diagnosis,
Gout and Hyperuricemia: Diseases Beyond the Joint ................81 Clinical Subsetting and Predicting Outcomes ......................91
Preclinical Autoimmunity – Potential for Prevention ................82
ARHP Sessions
ACR Concurrent Abstract Sessions Clinical and Epidemiologic Study Designs in Rheumatic
Cytokines, Mediators, and Gene Regulation II (#1658-1663). . . . . . . . . . 82 Disease Research ............................................91
Epidemiology and Health Services Research III: Rheumatic Don’t Let the Pink Sheets Make You Blue .........................91
Diseases and Cardiovascular Disease and Risk Assessment Fungal Infections and Tuberculosis in Patients with
(#1664-1669) ................................................82 Rheumatologic Disease (Infection Series). . . . . . . . . . . . . . . . . . . . . . . . . 91
Muscle Biology, Myositis and Myopathies: Pathogenesis in
ACR Meet the Professors Sessions
Idiopathic Inflammatory Myopathies (#1670-1675) ................83
Ankylosing Spondylitis: Disease Modification (061) .................91
Pediatric Rheumatology: Clinical and Therapeutic Disease II:
Juvenile Idiopathic Arthritis II (#1676-1681) ......................84 Crystal: Diagnosis and Management of Gout (062) .................92
Rheumatoid Arthritis – Clinical Aspects III: Rheumatoid Arthritis Infections with Biologics (063) ..................................92
and Cardiovascular Disease (#1682-1687) ........................84 Osteoarthritis: Update 2012 (064) ...............................92
Rheumatoid Arthritis – Human Etiology and Pathogenesis I: Pain: Dealing with Patients with Refractory Pain in
Early Pathogenesis of Rheumatoid Arthritis (#1688-1693) ...........85 Musculoskeletal and Autoimmune Disorders (065) .................92
Rheumatoid Arthritis Treatment – Small Molecules, Biologics Pediatrics: Juvenile Idiopathic Arthritis for Adult
and Gene Therapy: Safety II (#1694-1699) ........................85 Rheumatologists (066) ........................................92
Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects Pregnancy in Rheumatic Diseases (067) ..........................92
and Treatment: Spondyloarthritis II (#1700-1705) .................86
Reactive Arthritis: An Update (068) ..............................92
Systemic Lupus Erythematosus – Clinical Aspects and Treatment III:
Scleroderma: Systemic Sclerosis (069) ............................92
Cardiovascular (#1706-1711) ...................................87
Vasculitis: Update (070) ........................................92
Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s –
Clinical Aspects and Therapeutics II (#1712-1717) .................87 ACR/ARHP Workshops
Adult Musculoskeletal Lower Examinations (229) ..................92
ACR Meet the Professor Sessions
Knee Braces and Foot Orthosis for Knee Osteoarthritis (230) .........92
Adult Inflammatory Myopathy (051) .............................88
Peripheral Magnetic Resonance Imaging in Rheumatology
Antiphospholipid Syndrome (052) ...............................88
Practice (231) ...............................................92
Controversies in Sjögren’s Syndrome (053) ........................88
Synovial Fluid Analysis and Crystal Identification (232) ..............92
Dermatological Manifestations of Rheumatic Diseases (054) .........88
Fibromyalgia and Dysautonomia (055) ...........................88 ACR Sessions
Pain: Evaluation and Treatment of Back Pain (056) .................88 Advances in Targeting of B cell Survival Factors ....................92
Pediatric Systemic Lupus (057) ..................................88 Systems Immunology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
Psoriatic Arthritis (058) ........................................88 ARHP Sessions
Rheumatoid Arthritis: Biological Agents (059) .....................88 Hepatitis in Patients with Rheumatologic Disease
Systemic Lupus Erythematosus: Difficult to Treat Systemic Lupus (Infection Series) .............................................93
Erythematosus (060) .........................................88 Rheumatic Disease Update: The Approach to Low Back Pain .........93
ARHP Sessions Threats to Validity: Confounding in Rheumatic Disease
Research (Research Series) ....................................93
Early Rehabilitation for Hip and Foot Osteoarthritis:
Opportunities and Challenges ..................................88 ACR Sessions
Novel Approaches to Pain Management in Juvenile Contract Negotiations for Physicians .............................93
Idiopathic Arthritis ...........................................88
Paradigm Shifts in Rheumatoid Arthritis ..........................93
Promoting Participation: Where Is the Field and Where
The Guide to Meaningful Use and Beyond ........................93
Do We Go Next? .............................................89
6 2012 Program Book
TABLE OF CONTENTS
Rheumatology Research Foundation Special Session ACR Sessions
Disease Targeted Research .....................................94 Catastrophic Antiphospholipid Syndrome (Clinical Review) ..........102
Osteoimmunology ...........................................102
ARHP Concurrent Abstract Sessions
Physical/Occupational Therapy and Exercise in Patients ACR Study Groups ............................................102
with Rhematologic Disease (#2431-2436) ........................94
ACR/ARHP Workshops
Programs and Literacy in Patients with Rheumatolgic
Clinical Anatomy and Physical Exam: Essential Tools in
Diseases (#2437-2442) ........................................94
Upper Extremity Regional Pain Syndromes (235) .................103
ACR/ARHP Poster Session C, MRI in the Diagnosis and Management of Spondyloarthritis:
Thieves’ Market Posters and Poster Tours A Clinician’s Guide(236) ......................................103
Abstracts (#1724-2430) ........................................95 Synovial Fluid Analysis and Crystal Identification (237) .............103
Web-based Tools for Enhancing and Managing Teaching
Exhibits and Innovation Theater
and Clinical Practice (238) ....................................103
See page 316 of a complete listing of Innovation Theater. ............96
ACR Session
ACR Session
ACR Leadership Town Hall Meeting & Business Meeting ............103
Gouty Inflammation ..........................................96
ACR Sessions
ARHP Sessions
Approach and Management of Back Pain in Older Adults ...........103
Immunizations in Patients with Rheumatologic Disease
Connective Tissue Disease Associated Interstitial Lung Disease ......104
(Infection Series) .............................................96
New Molecules in Joint Biology ................................104
Selection Bias in Rheumatic Disease Research – Risk Factor
Paradox and Other Issues .....................................96 Visualizing the Immuno-inflammatory Response ..................104
ACR/ARHP Combined Abstract Session ACR Concurrent Abstract Sessions
ACR/ARHP Combined Rehabilitation Abstract Session ACR Late-breaking Abstract Session .............................104
(#2443-2448) ................................................96 Antiphospholipid Syndrome (#2455-2460) .......................104
Epidemiology and Health Services Research IV: Outcomes
ACR Workshops
and Costs in Rheumatic Disease (#2461-2466) ...................105
Histopathology of Vasculitis (233) ...............................97
Osteoarthritis – Clinical Aspects II: Structural Risks for
Joint Injection Techniques (234) .................................97
Osteoarthritis End-points and Potential Treatments
(#2467-2472) ...............................................105
ARHP Sessions
Pediatric Rheumatology: Clinical and Therapeutic Disease III:
A Practical Understanding of Function in Rheumatoid Arthritis:
Childhood Systemic Lupus Erythematosus and Other Vasculitides
A Multidisciplinary Perspective .................................97
(#2473-2478) ...............................................106
Strategies to Enhance Office Efficiencies and Access to Care
Rheumatoid Arthritis – Clinical Aspects IV: Non-biologic Drugs
in Rheumatology Practice .....................................97
for Rheumatoid Arthritis: New Insights on Comorbidities and
ACR Plenary Session III: Discovery 2012 Adverse Events (#2479-2484) .................................107
Abstracts (#2449-2454) ........................................97 Rheumatoid Arthritis Treatment – Small Molecules, Biologics
and Gene Therapy: Safety & Efficacy of Janus Activated-Kinase
ACR Sessions
(JAK) Inhibitors (#2485-2490) .................................108
Microbiome Influence on Autoimmunity ........................101
Spondyloarthritis and Psoriatic Arthritis – Pathogenesis,
Polymyalgia Rheumatica – Recent Advances and Ongoing Questions ...101 Etiology (#2491-2496) .......................................108
Top 10 Compliance Risks Facing Physicians .......................101 Systemic Lupus Erythematosus – Human Etiology and
Pathogenesis II (#2497-2502) .................................109
ARHP Networking Event
T-cell Biology and Targets in Autoimmune Disease (#2503-2508) .....109
Networking Break ...........................................102
ACR/ARHP Combined Abstract Session
ACR Meet the Professor Sessions
ACR/ARHP Combined Epidemiology Abstract Session (#2509-2514) ..110
Basic Immunology for Clinical Rheumatologists (071) ..............102
Fibromyalgia and Dysautonomia (072) ..........................102 ARHP Sessions
Myopathy: Issues in Diagnosis and Treatment (073) ...............102 Myositis: Pathogenesis, Diagnosis and Management ...............110
Rheumatoid Arthritis: Challenging Cases (074) ....................102 Rheumatic Disease Update: Systemic Lupus Erythematosus .........111
Rheumatoid Arthritis: Safety of Novel Therapies (075) .............102 Rheumatoid Arthritis Disease Activity Measures and Quality
Indicators: Correct Use and Future Directions ....................111
Systemic Lupus Erythematosus: Central Nervous System (076) ......102
Transition Tools for Patients: Pediatric to Adults ...................111
Systemic Lupus Erythematosus: Difficult to Treat Systemic Lupus
Erythematosus (077) ........................................102 ACR Workshop
Systemic Lupus Erythematosus: Lupus Nephritis (078) .............102 Joint Injection Techniques (239) ................................111
Temporal Arteritis (079) ......................................102
Vasculitis: Update (080) .......................................102
2012 Program Book 7
TABLE OF CONTENTS
ARHP Session The Unintended Consequences of Health Information
Obesity: It is a Chronic Disease .................................111 Technology ................................................121
ACR Session ARHP Sessions
Diagnostic Assessments in Myopathy ...........................111 An Introduction to Immunology ................................121
MicroRNA and the Rheumatic Diseases ..........................112 Beyond the Basics: A Real Life Example of Multiple Imputation
for Missing Data Problems (Research Series) .....................121
Should Ultrasound be Used in Rheumatology Practice? ............112
The Great Masqueraders: Malignancies in Rheumatic Disease .......112 ACR Sessions
Biosimilars Development: Food and Drug Administration
ACR Concurrent Abstract Sessions
Perspective ................................................122
Biology and Pathology of Bone and Joint: Regulation of
IgG4-Related Disease – Past Lessons and Future Directions .........122
Bone Cells (#2515-2520) .....................................112
NIAMS-Sponsored Research in Rheumatology: 2012 Highlights ......122
Innate Immunity and Rheumatic Disease (#2521-2526) ............113
Osteoarthritis Therapeutics: Will This be the Decade for
Miscellaneous Rheumatic and Inflammatory I (#2527-2532) ........113
Breakthroughs? .............................................122
Osteoarthritis – Clinical Aspects I: Weight, Activity, and
Predictive Biomarkers: A Journey to Personalized Health Care .......123
Metabolic Effects on Osteoarthritis (#2533-2538) .................114
Rheumatoid Arthritis – Clinical Aspects V: Comorbidities in ACR Concurrent Abstract Sessions
Rheumatoid Arthritis (#2539-2544) ............................115 B-cell Biology and Targets in Autoimmune Disease (#2575-2580) ....123
Rheumatoid Arthritis Treatment – Small Molecules, Biologics Imaging of Rheumatic Diseases III: Computed Tomography
and Gene Therapy: Efficacy of Approved Biologics (#2545-2550) ....115 (#2581-2586) ...............................................123
Sjögren’s Syndrome II – Clinical (#2551-2556) ....................116 Medical Education (#2587-2592) ...............................124
Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects Pediatric Rheumatology: Clinical and Therapeutic Disease IV:
and Treatment: Psoriatic Arthritis (#2557-2562) ..................117 Childhood Therapeutics and Response (#2593-2598) ..............124
Vasculitis: Clinical Aspects (#2563-2568) .........................118 Quality Measures and Innovations in Practice Management
and Care Delivery (#2599-2604) ...............................125
ACR Meet the Professor Sessions
Rheumatoid Arthritis – Clinical Aspects VI: Remission and Flare
Central Nervous System Vasculitis (081) .........................119
in Rheumatoid Arthritis (#2605-2610) ..........................126
Crystal: Pseudogout (082) .....................................119
Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects
Effective Use of Technology (083). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119 and Treatment: Psoriatic Arthritis and Spondylarthritis
Pulmonary Manifestations of Rheumatic Disease (084) .............119 (#2611-2616) ...............................................126
Raynaud’s and Digital Ischemia (085) ............................119 Systemic Lupus Erythematosus – Clinical Aspects and Treatment IV:
Rheumatoid Arthritis: Safety of Novel Therapies (086) .............119 Therapeutics (#2617-2622) ...................................127
Rheumatology Practice 101: Starting Out in Practice for ARHP Sessions
The Graduating Fellow (087) ..................................119
Forming An Education and Support Group from the Ground Up .....128
Systemic Lupus Erythematosus: Lupus Nephritis (088) .............119
Osteoporosis: 2012 Update ...................................128
Systemic Lupus Erythematosus: Novel Treatments (089) ............119
ARHP Concurrent Abstract Sessions
Vaccinations for Patients on Biologic Therapies (090) ..............119
Systemic Sclerosis, Vasculitis, Crohn’s and Spondylarthropathies
Rheumatology Research Foundation Special Session (#2623-2628) ...............................................128
Edmond L. Dubois, MD Memorial Lectureship: Clinical and Rehabilitative Aspects of Osteoarthritis (#2629-2634) ...129
Hydroxychloriquine Reduces Thrombosis in Systemic Lupus
Erythematosis Particulerly in Antiphospholipid Positive Patients ACR Sessions
(#2569-2574) ...............................................119 Amyloidosis 2012 ............................................129
Mechanisms of Autoinflammatory Diseases ......................129
ARHP Sessions
Arthritis and the Older Worker .................................120 ACR Sessions
Best Practices for Ordering Diagnostic Imaging in Evaluating Making Sense of Autoantibodies in the Diagnosis of Systemic
Rheumatologic Conditions ....................................120 Rheumatic Diseases .........................................129
The Puzzle of Fatigue in Rheumatoid Arthritis: Putting the Rheumatoid Arthritis – Treating to Target: How to Incorporate
Pieces Together .............................................120 Rheumatoid Arthritis Disease Activity Measures into Routine
Practice ...................................................130
Wednesday, November 14, 2012
ACR Concurrent Abstract Sessions
ACR Sessions
Epidemiology and Health Services Research V: Rheumatoid
Immunology of Pregnancy and Impact on Autoimmune
Arthritis Management in the Treat-to-Target Era (#2635-2640) ......130
Pathogenesis ...............................................121
Fibromyalgia and Soft Tissue Disorders II (#2641-2646) .............130
Neutrophil Extracellular Traps (NETosis) in Rheumatic Disease .......121
Orthopedics, Low Back Pain, and Rehabilitation (#2647-2652) .......131
Rheumatology Roundup: Highlights from the 2012 Annual
Pediatric Rheumatology – Pathogenesis and Genetics
Scientific Meeting ...........................................121
(#2653-2658) ...............................................131
8 2012 Program Book